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230 Abstract
31 RON receptor tyrosine kinase is a transmembrane protein directly involved in suppression of 
32 inflammation and its aberrant expression linked to cancers and metastasis. Efforts to block 
33 deregulated RON signaling in tumors using small molecule kinase inhibitors or antibodies have 
34 been complicated by the presence of unknown number/types of isoforms of RON, which, despite 
35 being structurally similar, localize differently and mediate varied functions. Current study was 
36 designed to identify the splice variants of RON transcripts formed by skipping of sequences 
37 between exons 9 and 14 for better understanding of isoform specific RON signaling in cancers. 
38 PCR amplification and bi-directional sequencing of a 901bp cDNA sequence located between 
39 exons 9 to 14 of RON from lung cancer cell lines revealed the presence of two splicing variants 
40 formed by skipping of exons 11 and 11-13.  Each of these transcripts was found in more than one 
41 cell line. Expressed sequence tag (EST) database search indicated that the splicing variant lacking 
42 exons 11-13 was a novel one. Here we conclude that the splice variants of RON lacking exon 11 
43 and exons 11-13 were detected in several lung cancer cell lines. Novel variant formed by skipping 
44 exons 11-13, the sequence of which code for transmembrane region, is predicted to code for a 
45 truncated isoform that may be secreted out. Tumors may antagonize the ligand dependent anti-
46 inflammatory function of wild-type RON by secreting out the ligand binding isoforms.  
47 Keywords: alternative splicing; lung cancer; macrophage stimulating protein (MST1R); receptor 




52 RON, also known as MST1R (macrophage-stimulating 1 receptor), is a member of the MET family 
53 of receptor tyrosine kinases (RTKs). MSP (macrophage stimulating protein, the ligand for RON) 
54 driven RON signaling has been shown to be anti-inflammatory via many models (Correll et al., 
55 1997; Liu et al., 1999; Waltz et al., 2001). MSP/RON signaling is activated in macrophages 
56 following acute inflammation and serves to suppress synthesis of pro-inflammatory mediators like 
57 nitric oxide (NO), prostaglandins and several other pro-inflammatory cytokines and upregulate 
58 anti-inflammatory cytokines like IL-10 (Gunella et al., 2006). RON activation also blocks NF-
59 kappaB activation (Zhou et al., 2002), and further is a critical determinant of macrophage 
60 activation states (M1/M2) (Sharda et al., 2011).
61 Ample evidence indicate deregulated expression and functioning of RON in a number of cancers 
62 (Gaudino et al., 1995; Wang et al., 1996; Sakamoto et al., 1997; Maggiora et al., 1998; Wang et 
63 al., 2000; Camp et al., 2007; Zhou et al., 2008; Kretschmann et al., 2010). While RON 
64 overexpression is associated with tumor aggressiveness and metastasis (Thomas et al., 2007), 
65 knockdown of RON expression in different cancer cell lines using siRNA/shRNA showed 
66 suppression of tumorigenic properties (Xu et al., 2004; Wang et al., 2009; Logan-Collins et al., 
67 2010). Validation of overexpressed RON as a therapeutic target in tumors has been hampered due 
68 to the simultaneous production of its several isoforms. Previously, protein expression analyses  
69 indicated the absence of wild type RON but its isoforms present in lung cancer cell lines could not 
70 be detected with Western blotting (Kanteti et al., 2012). Several variant transcripts and their protein 
71 products have been described for RON in various cancer cell lines as well as solid and pleural 
72 tumors (Lu et al., 2007). Despite exhibiting diverse functions in cancers, the isoforms show 
73 considerable sequence similarity and to the wild type RON. The isoforms include both active 
474 (Wang et al., 2000; Angeloni et al., 2007; Zhou et al., 2008) as well as various N-terminally 
75 truncated dominant negative variants (Lu et al., 2007; Jin et al., 2008; Eckerich et al., 2009; Ma et 
76 al., 2010). Ectopic expression of some RON splice variants in NIH3T3 cells induced tumor 
77 formation in vivo (Zhou et al., 2003). 
78 We hypothesize that aberrant expression of RON via alternative splicing in cancers may alter its anti-
79 inflammatory role and hence structural and functional characterization of the individual isoforms may 
80 elucidate their role in cancer development. Recently, we reported the presence of several, frequently 
81 occurring novel transcript variants affecting the intracellular region of RON in lung cancer cell lines 
82 (Krishnaswamy et al., 2015; Krishnaswamy et al., 2016). In this study, we focused on RON mRNA 
83 sequence between exons 9 and 14 to identify any novel splicing variants, using various lung cancer 
84 cell lines, by PCR amplification and sequencing. 
85 Materials and Methods
86 Cell lines
87 SCLC cell lines H526, H446, H249, H69, H2171, H345, H82, H146, H889 and H524 and 
88 NSCLC cell lines SW1573, H358, A549, H1838, H661, H522, H1437, H2170, SW900, H1993, 
89 SKLU-1, H1703 and SKMES were obtained from ATCC (Manassas, VA) and were cultured in 
90 RPMI 1640 medium (Gibco/BRL) supplemented with 10% (v/v) fetal bovine serum supplemented 
91 with L-glutamine and 1% (v/v) penicillin/streptomycin at 37°C with 5% CO2. 
92 cDNA preparation, PCR and sequencing 
93 Total RNA from the cell lines was isolated using TRIZol reagent (Invitrogen, Carlsbad, CA, USA) 
94 following manufacturer’s instructions. cDNA was generated using 1μg of total RNA and oligo dT 
95 primer by using Single Strand cDNA Synthesis Kit (Clontech, Palo Alto, CA, USA). cDNAs of 
96 RON were amplified thermal cycler using specifically designed primers covering 901 bps of RON 
597 reference mRNA sequence (NM_000247) using forward primer (located in exon 9) 5′- 
98 CAGCATCTAACTTCAGCATGGCACTTAG - 3′ and reverse primer (located in exon 14) 5′- 
99 CAGTGACCGAGTCATTGGCAAAG - 3′. Sequencing was performed in final volume of 10μl. 
100 BigDye® Terminator (V 3.1) Sequencing reactions were carried out by using 0.4 pmole of either 
101 forward or reverse primers. The 10μl reaction consisted of 0.5-1μl of BigDye mix, 1.5μl of 5X 
102 sequencing buffer (Tris HCl 400 mM pH 9, MgCl2 10 mM) and 5-6μl purified PCR product.  
103 Sequencing PCR reaction mixes were initially denatured at 96C for 1 minute and 30 seconds, 
104 followed by 35 cycles of denaturation at 96C for 45 seconds and annealing at 50C for 30 seconds, 
105 and extension at 60C for 4 minutes. Sequencing PCR products ere purified and dissolved in 12μl 
106 Hi-DiTM formamide before loading on a genetic analyzer (Applied Biosystems PRISM 310, 
107 Foster City, CA). Sequence variations in the PCR products were identified by aligning sequencing 
108 chromatograms with reference RON sequence using Mutation Surveyor version 3.1 software 
109 (SoftGenetics, State College, PA). The numbering of nucleotide positions is relative to the first 
110 base of the translational initiation codon of the full-length RON coding sequence (CCDS 2807.1).
111 Results
112 A number of alternatively spliced forms of RON mRNA and their protein products have previously 
113 been reported. However, amplifying the entire coding sequence of RON (4200 bps) as a single 
114 amplicon and sequencing would have failed to provide a complete picture of all the alternative 
115 splicing events due to the formation of multiple products possessing largely similar sequences. 
116 Hence, we amplified a short section of RON mRNA, covering region between exons 9 and 14, by 
117 converting to cDNA and using forward and reverse PCR primer sequences located in exons 9 and 
118 14, respectively (Figure 1). Sequence chromatograms were obtained using the forward 
119 amplification primer for NSCLC cell line H661 indicated the presence of a predominant variant 
6120 lacking exon 11 (Figure 2). This splicing variant was also found in A549, SKLU1, A249, H69, 
121 H82, H345 and H526 cell lines.
122 Chromatograms of cell line H249 were obtained by sequencing from 5′ end indicated the co-
123 occurrence of two splice variants, one formed by skipping of exon 11 and the other formed by 
124 skipping of exons 11-13. Further, exon 10 of the major variant (based on peak heights) ended with 
125 TTTTAG sequence, while it ended with TTT in the minor variant due to the deletion of the last 
126 three (TAG) nucleotides. Two additional overlapping new sequences starting at nucleotide 2650 
127 (of RON reference sequence) were also identified; these sequences corresponded to starting 
128 nucleotides of exons 12 and 14, identifying them as distinct splicing variants arising from the loss 
129 of exon 11 and exons 11-13, respectively. Exon 11 containing wild type/reference RON transcript 
130 sequence was completely missing from H249 PCR products. Skipping of exon 11 results in an in-
131 frame deletion of 147 nucleotides, corresponding to 49 amino acids, and skipping of exons 11-13 
132 leads to loss of 415 nucleotides and consequently a frame-shift leading to the appearance of 
133 premature termination codon. RON splicing variant lacking exons 11-13 was also found in H358, 
134 H146, H524, A549, SKLU1, SKMES, H69, H1703, H1993, H82, and H889 cell lines (Figure 3). 
135 The overlapping of sequences started at nucleotide 3066 of RON reference sequence and the two 
136 overlapping sequences matched with exons 10 and 13 of the reference sequence in H1993. This 
137 confirmed the presence of the splicing variant formed by loss of exons 11-13, which occurred 
138 along with the wild-type transcript.  Furthermore, from the size of the peaks, alternatively spliced 
139 transcript variant was identified at a higher level than the wild-type transcript. In this cell line, only 
140 the splicing variant whose exon 10 sequence ends with bases TTTGAG was found (Figure 4). 
141 Intron sequence located between exons 9 and 10 was spliced out in two different ways in H1993 
142 (Figure 5): the last three nucleotides of this intron (CAG) were retained in the minor (based on 
7143 peak heights) splicing variant, while these nucleotides were not included in the major splicing 
144 variant. The splicing variant that retained CAG at the beginning of exon 10 ended up losing the 
145 last three nucleotides, GAG, of exon 10, as shown in H249 cell line (Figure 3). 
146 Discussion
147 Aberrant expression of RON in tumors is accompanied by alternative splicing of mRNA transcripts 
148 leading to expression of an array of isoform products having varying functions. However, high 
149 level of sequence similarities among the transcript variants and their protein isoforms pose 
150 problems in specific target discovery and validation. In this study, we screened lung cancer cell 
151 lines for splicing variants between exons 9 and 14 of RON transcripts through partial cDNA 
152 sequencing. Results revealed the presence of a novel alternatively spliced variant lacking exons 
153 11-13 and a previously known variant formed by skipping of exon 11. Both these variants occurred 
154 together in several cell lines. Both variants were found with or without deletion of the last three 
155 nucleotides of exon 10, GAG, which codes for glutamic acid. This single codon difference between 
156 transcript variants was created by differential splicing of exon 10. Exon 12 contains sequence 
157 coding for transmembrane (TM) domain, and skipping of exons 11-13 leads to frame-shift and 
158 appearance of premature termination codon. Translation product of transcript variant lacking 
159 exons 11-13 is expected to be secreted and the produced isoform may block MSP/RON signaling 
160 by binding to MSP or by dimerizing with normal RON, by making N-terminally truncated isoforms 
161 of RON. Thus, tumors may nullify the anti-inflammatory/anti-carcinogenic role of MSP/RON 
162 signaling via altering the splicing pattern of RON RTK. 
163 Two RON transcripts involving differential splicing of exon 11 have been reported previously; 
164 one of these lacked exons 5, 6 and 11 and the other lacked only exon 11. Skipping of exon 11 
165 caused an in-frame deletion of 147 nucleotides, corresponding to 49 amino acids of the 
8166 extracellular region of RON beta chain, resulting in RONdelta165, a constitutionally active 
167 cytoplasmic isoform (Zhou et al., 2003; Lu et al., 2007). Transcript lacking exons 5, 6 and 11 was 
168 translated into RONdelta155, a cytoplasmic isoform of RON that was also constitutively active 
169 (Zhou et al., 2003; Lu et al., 2007). Partial splicing of exons 5 and 6 (P5P6) produces a RON 
170 isoform that lacks the first extracellular immunoglobulin-plexin-transcription domain which 
171 express in human pancreatic cancer (Chakedis et al, 2016). The expression of RON wildtype, 
172 p165, p160, and p155 transcripts were studied in different cancer tissues. The higher expression 
173 of RON transcripts was noted in lung, gastroesophageal, and colon tissues (both normal and 
174 cancerous) than breast, prostate, and ovarian tissues (both normal and cancerous) 
175 (Wortinger and Liu, 2008).  We used an antibody specific for amino acids 531-690 of the 
176 extracellular region of beta RON for Western blot analysis in NSCLC and SCLC cell lines but no 
177 expression of RON was found. 
178 RON splicing variant lacking exons 11-13 is the novel finding of this study.  Defective splicing 
179 reactions causing large deletions and appearance of early termination codons in mRNAs have been 
180 reported to be degraded via non-sense mediated decay (NMD). Even though the deleted sequence 
181 is large (415 nucleotides) and deletion of exons 11-13 result in appearance of early termination 
182 codon, this transcript is not expected to undergo NMD; this is because alternatively spliced RON 
183 transcript lacking exon 6, which acquires a premature early termination codon caused by frame-
184 shift, was shown to yield a viable isoform, RONdelta90 (Eckerich et al., 2009). Also, RONdelta85 
185 was shown to be an N-terminally truncated isoform of RON formed due to retention of 49 bases 
186 of intron 5 (lying between exons 5 and 6) and consequently undergoing a reading-frameshift (Ma 
187 et al., 2010). We expect that the translation product of transcript variant lacking exons 11-13 may 
188 be secreted extracellularly in a fashion similar to the two isoforms, RONdelta90 and RONdelta85. 
9189 The isoform product coded by transcript variant lacking exons 11-13 is predicted to act in a 
190 dominant negative fashion and block MSP stimulated RON signaling, as in the case RONdelta85 
191 and RONdelta90 (Eckerich et al., 2009; Ma et al., 2010). We speculate that the constitutively active 
192 isoform, encoded by transcript lacking exon 11, and the dominant negative isoform, which may 
193 serve to block ligand dependent RON signaling, together may enable tumors acquire ligand (MSP) 
194 independent RON signaling. 
195 One of the primary hallmarks of cancer is growth factor independent signaling. However, how 
196 cancer cells achieve this is not yet understood and more research on dominant negative isoforms 
197 produced by cancer cells may shed light on this aspect. Ubiquitous presence of RON isoforms 
198 exhibiting dominant negative functions, such as the secreted ones capable of nullifying the effect 
199 of ligand (MSP), truncated transmembrane or cytoplasmic isoforms capable of dimerizing with 
200 wild type RON, in cancer also raises important questions regarding the appropriateness of targeting 
201 wild type RON, which in fact may lead to tumors. 
202 Identification and characterization of all the transcript variants and their protein products is 
203 essential for RON target validation in cancer therapeutic development. Presence of alternatively 
204 spliced transcripts lacking different coding regions in tumor cells is expected to interfere with 
205 estimation of wild type RON expression, either by immunological or PCR methods, leading to 
206 exaggerated values. Further, application of siRNAs, which usually lack transcript variant 
207 specificity, may knockdown different transcripts affecting results of correlational studies (Celotto 
208 and Graveley, 2002).  In this context, several genes and their protein products have been found to 
209 exert dual roles as tumor suppressors and stimulators, but the specific underlying mechanisms are 
210 yet to be determined (Perkins, 2004; Krisenko and Geahlen, 2015).  A complete understanding, at 
211 a structural and functional level, of the various transcription products of RON is expected to lead 
10
212 to resolving the mechanism underlying their specific roles in cell signaling regulation and cancer 
213 development and eventually help us to target its cancer specific signaling. 
214 Conclusion
215 Tumors are normally screened for RON expression in target identification and validation studies. 
216 Even though the functions of many of its isoforms may be different and even oppose each other in 
217 some cases, current methods for quantification and functional analysis of RON cannot distinguish 
218 between its isoforms. This study describes the identification of a novel alternatively splice site 
219 sequence variant of RON that may affect its transmembrane localization. Sequence 
220 characterizations presented here together with knowledge of previously identified isoforms point 
221 to the need for design and application of isoform specific primers, siRNAs and antibodies for more 
222 accurate isoform – functional correlational studies and the therapeutic development. Further, 
223 inflammation is expected drive tumor development as well as metastasis and aberrant expression 
224 of RON by tumors - via alternative splicing of transcripts - may attenuate its anti-inflammatory 
225 functions.
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349 Figure 1. Schematic diagram showing structural features of RON. A: various domains of RON 
350 protein and two juxtaposed tyrosine residues at position 1238 and 1239 respectively (Y-Y) in the 
351 kinase domain; carboxy-terminal docking site for multiple substrates with src homology 2 (SH2) 
352 domain contains two phosphorylation sites for tyrosine at amino acid positions 1353 and 1360; B: 
353 20 coding exons of RON with exons are shown in proportion to length; C: PCR amplified and 
354 sequenced segment of RON coding sequence, lying between exons 9 and 14; starting nucleotide 
14
355 numbers are given for each exon. D: cDNA obtained from different cell lines were PCR amplified 
356 using pairs of primers covering increasing lengths RON cDNA sequence. The agarose gel 
357 showing fragment sizes above the wells. Results indicate the presence of increasing number of 
358 transcripts with increasing amplicon size for each of the cell lines. 
359
360 Figure 2. RON splicing variant lacking exon 11 from cell line H661. PCR amplification product 
361 of RON cDNA from cell line H661 sequenced from 3′ end showing deletion of exon 11. The only 
362 splicing variant in the sequencing chromatogram, as seen from peak heights, lacked 147 
363 nucleotides, from 2650 to 2796, corresponding to exon 11 (minor peaks in this sequencing 
364 chromatogram were not analyzed) of RON reference cDNA sequence. 
365 Figure 3. Splicing variants lacking exon 11 and exons 11-13 from cell line H249. PCR 
366 amplification product of RON cDNA from cell line H249 sequenced from 5′ end showing the 
367 presence of two splicing variants; one caused by loss of exon 11 and the other caused by loss of 
368 exons 11-13. Exon 10 of the major variant (based on peak heights) ends with TTTGAG sequence, 
369 while the same exon ends with TTT in the minor variant due to the skipping of nucleotides GAG. 
370 Figure 4. RON splicing variant lacking exons 11-13 from cell line H1993. RON cDNA PCR 
371 product of cell line H1993 sequenced from 3′ end showing the presence of alternatively spliced 
372 transcript variant formed due to deletion of exons 11-13. 
373 Figure 5. Differential splicing of exon 10 in RON transcripts of H1993. RON cDNA PCR 
374 product of cell line H1993 sequenced from 5′ end showing inclusion of nucleotides CAG at the 
375 beginning of exon 10 when compared to reference RON sequence. During the formation of 
376 reference RON transcript, CAG, which was part of the intron was spliced out. 
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